Please login to the form below

Not currently logged in
Email:
Password:

Pfizer rides out Sanofi and confirms $14bn Medivation takeover

Success of cancer specialist’s drug Xtandi followed by work on other cancer drugs

Pfizer HQ building 

Pfizer has agreed a $14bn deal to acquire Medivation, enticing the cancer specialist away from other big pharma suitors.

The US pharma group announced this morning that an $81.50-per-share offer for Medivation had been accepted. that the final figure represents a huge premium to a $52.50 bid tabled by Sanofi earlier this year, later raised to $58 with an extra $3 in contingent value rights.

Medivation rejected both those offers out of hand but later agreed to open its books for scrutiny - although not exclusively to Sanofi. Pfizer, Novartis, Celgene, Merck & Co, Gilead and AstraZeneca have all been mentioned in connection with a possible takeover in recent weeks.

Medivation is in demand as it already has one very successful drug on the market - prostate cancer treatment Xtandi (enzalutamide) - as well as a well-regarded pipeline headed by PARP inhibitor talazoparib, which is in phase III trials in BRCA-positive breast cancer, and brain cancer candidate pidilizumab.

Partnered with Astellas, Xtandi made $1.9bn in sales last year and is on course to show impressive growth once again in 2016, with first-half sales upwards of $1.1bn and a claimed market share of 51% in the prostate cancer hormonal therapy market. 

There is plenty of room for further growth of Xtandi, according to analysts. Medivation is waiting for an FDA verdict on new labelling from a head-to-head trial comparing Xtandi to bicalutamide - already in the EU label for the drug.

Meanwhile, the company is also hoping phase III trials will support the expansion of the drug's use into non-metastatic castration-resistant prostate cancer as well as breast cancer. It is also waiting on the outcome of its first talazoparib registration trial early next year.

In April, Pfizer scrapped a planned merger with Allergan after the deal fell foul of a change in US tax laws, and there has been speculation that the US pharma giant is actively seeking out other M&A opportunities.

Article by
Phil Taylor

22nd August 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics